Non-Hodgkin Lymphoma | Specialty

Acute Myeloid Leukemia: Novel Targeted Therapies

December 6th 2017

NHL Studies: CAR T Therapy, Rituximab Maintenance, & PD-L1

December 6th 2017

New Data for Mantle Cell Lymphoma

December 6th 2017

Hodgkin Lymphoma: Upfront Brentuximab Vedotin + AVD

December 6th 2017

Pre-Conference Perspectives on Hematologic Malignancies

December 6th 2017

Ibrutinib Combo Improves PFS in Waldenstrom Macroglobulinemia

December 6th 2017

The combination of ibrutinib (Imbruvica) plus rituximab (Rituxan) improved progression-free survival versus rituximab alone in patients with Waldenström macroglobulinemia.

Expert Emphasizes Appropriate Diagnosis, Staging of T-Cell Lymphomas

December 1st 2017

Sunita D. Nasta, MD, compares the biology of peripheral and cutaneous T-cell lymphomas and offered advice on the optimal therapeutic approaches for either disease with novel agents.

FDA Grants Mogamulizumab Priority Review for CTCL

November 28th 2017

The FDA has granted a priority review to a biologics license application for mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

Dr. O'Connor on the Role of Obinutuzumab in Follicular Lymphoma

November 28th 2017

Owen O'Connor, MD, PhD, professor of medicine and Experimental Therapeutics, director of the Center for Lymphoid Malignancies, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, discusses the role of obinutuzumab (Gazyva) in the treatment of patients with follicular lymphoma.

Dr. Winter Discusses Copanlisib in Follicular Lymphoma

November 18th 2017

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses copanlisib (Aliqopa) in follicular lymphoma.

Dr. Epperla on FDA Approval of Frontline Obinutuzumab in Follicular Lymphoma

November 16th 2017

Narendranath Epperla, MBBS, MS, hematologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of frontline obinutuzumab (Gazyva) for the treatment of patients with follicular lymphoma.

FDA Approves Frontline Obinutuzumab for Follicular Lymphoma

November 16th 2017

The FDA has approved obinutuzumab (Gazyva) in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment of patients with advanced follicular lymphoma.

Brentuximab Vedotin Nears European Approval for CTCL

November 15th 2017

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of brentuximab vedotin (Adcetris) in adults with CD30-positive cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

Dr. Hamlin on Key Points of a Study on Cerdulatinib in Non-Hodgkin Lymphoma

November 7th 2017

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a phase II study investigating cerdulatinib in patients with non-Hodgkin lymphoma.

Tisagenlecleucel Submitted for European Approval for ALL, DLBCL

November 7th 2017

The European Medicines Agency (EMA) has received a Marketing Authorization Application (MAA) for tisagenlecleucel (Kymriah) for 2 forms of advanced lymphoma.

R-CVP Associated with 83% 8-Year OS for Advanced Symptomatic Follicular Lymphoma

November 3rd 2017

According to phase III results from the FOLL05 trial, the combination of rituximab plus cyclophosphamide, vincristine, and prednisone produced survival results comparable with standard-of-care regimens in patients with advanced symptomatic follicular lymphoma.

EFS at 24 Months May Predict Overall Survival in PTCL

November 2nd 2017

Patients with peripheral T-cell lymphoma are more likely to have superior overall survival if they have previously demonstrated event-free survival at 24 months.

Novartis Submits sBLA for Tisagenlecleucel in Adults With Relapsed/Refractory DLBCL

October 31st 2017

Novartis has filed a supplemental biologics license application with the FDA to expand the indication for tisagenlecleucel (Kymriah) to include adults with relapsed/refractory DLBCL who are ineligible for ASCT.

EZH2 Inhibitor Tested as Epigenetic Option in NHL Types

October 26th 2017

Tazemetostat, a small molecule that targets epigenetic activity of the EZH2 gene, is being investigated as a treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma or follicular lymphoma.

No Benefit With Prolonged Native E. Coli Asparaginase in Pediatric ALL, NHL

October 25th 2017

Treatment with prolonged native E. coli asparaginase therapy for children with acute lymphoblastic leukemia or non-Hodgkin lymphoma not only failed to improve survival versus the standard regimen, but also resulted in an increase in infections and allergy.